Skip to main content

Table 1 (abstract P44). Long-term efficacy with 52-week open-label erenumab treatment after 12-week double-blind treatment in patients with chronic migraine

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  Treatment failure subgroup 52-week OLE completers by last dose received
Erenumab 70 mg/140 mgN=416 Erenumab 70 mgN=189a Erenumab 140 mgN=137a
OLE visit weeks Week 12n=395 Week 40n=300 Week 52n=261 Week 40n=166 Week 52n=150 Week 40n=124 Week 52n=109
Change from BLb in MMD, mean (SE) −6.84 (0.32) −7.75 (0.38) −8.58 (0.41) −7.16 (0.48) −7.86 (0.52) −8.58 (0.62) −9.66 (0.65)
Change from BLb in MSMD, mean (SE) −4.17 (0.26) −4.78 (0.29) −5.56 (0.34) −4.75 (0.38) −5.47 (0.43) −4.93 (0.47) −5.75 (0.54)
Percentage of patients with ≥50% responsec(95% CI) 40 (35, 44) 50 (44, 56) 55 (49, 61) 43 (36, 51) 49 (41, 57) 60 (51, 68) 63 (54, 72)
  1. aBased on the final dose of erenumab received. Patients in the erenumab 140 mg group received ≥3 months of erenumab 140 mg at Week 40 and ≥6 months of erenumab 140 mg at Week 52. bParent study baseline. c≥50% reduction in MMD from parent study baseline
  2. BL, baseline; CI, confidence interval; MMD, monthly migraine days; MSMD, monthly acute migraine-specific medication treatment days; N, number of patients enrolled in the OLE and who failed ≥1 prophylactic treatment; n, number of patients with observed data at each time point; OLE, open-label extension; SE, standard error